Key Findings
Profusa, a digital health company, has announced significant advancements toward achieving CE Mark approval for its flagship product, the Lumee® Oxygen Platform. The company has received a favorable decision from GMED, a European Notified Body, concerning its ISO 13485 quality management system certification, with formal certification anticipated in early October. This certification is a crucial step demonstrating conformity with the European Medical Device Regulation (MDR) and is expected to accelerate product deployment in the European market.
Technical & Clinical Details
The Lumee® Oxygen Platform comprises proprietary injectable, tissue-integrated biosensors. These micro-sensors are subcutaneously implanted as tiny hydrogel structures, designed to continuously monitor tissue oxygen levels in real-time for several months. The implanted sensors are non-invasively read by a dedicated external reader, providing vital data such as oxygen saturation and partial pressure. This data is highly valuable for clinicians in making informed decisions in critical clinical scenarios where tissue oxygen supply is paramount, such as in specific ischemic conditions (e.g., peripheral artery disease, diabetic foot ulcers) and for monitoring graft viability. The ISO 13485 certification attests that Profusa’s processes meet international standards for quality and safety across all stages of medical device design, development, production, installation, and service, thereby underpinning product reliability.
Background & Context
Accurate and continuous monitoring of tissue oxygen levels is vital for the diagnosis, treatment planning, and prognostic assessment of certain medical conditions. However, previous technologies faced limitations, including intermittent measurements, invasiveness, or an inability to accurately reflect deep tissue oxygen levels. Profusa’s technology overcomes these challenges by combining highly biocompatible injectable sensors with wireless reading technology. The rigorous conformity assessment process for the European MDR, coupled with ISO 13485 certification, provides robust evidence that Profusa’s product adheres to the highest standards of quality and safety. This signifies a major advancement in the field of digital health and implantable biosensors.
Strategic Significance & Outlook
The impending CE Mark approval for the Lumee® Oxygen Platform will pave the way for Profusa’s market entry in Europe and has the potential to redefine the standard for tissue oxygen monitoring. This technology is expected to improve patient outcomes by enabling more personalized treatment strategies in the management of ischemic diseases, post-surgical monitoring, and wound healing assessment. Looking ahead, there is potential for the Lumee platform to expand beyond oxygen to monitor other biomarkers, contributing to diagnosis and management across a broader range of disease areas. This advancement further underscores the evolution of continuous in-vivo monitoring technologies and the transformative impact digital health is bringing to medical practice.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments